|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial显示文摘We aimed to evaluate the effectiveness and safety of single-course initial regimens in patients with low-risk gestational trophoblastic neoplasia(GTN).In this trial (NCT01823315),276 patients were analyzed.Patients were allocated to three initiated regimens:single-course methotrexate(MTX),single-course MTX+dactinomycin(ACTD),and multi-course MTX(control arm).The primary endpoint was the complete remission(CR)rate by initial drug(s).The primary CR rate was 64.4%with multi-course MTX in the control arm.For the single-course MTX arm,the CR rate was 35.8%by one course;it increased to 59.3%after subsequent multi-course MTX,with non-inferiority to the control(difference-5.1%,95%confidence interval(CI)-19.4%to 9.2%,P=0.014).After further treatment with multi-course ACTD,the CR rate(93.3%)was similar to that of the control(95.2%,P=0.577).For the single-course MTX+ACTD arm,the CR rate was 46.7%by one course,which increased to 89.1%after subsequent multi-course,with non-inferiority(difference 24.7%,95%CI 12.8%-36.6%,P<0.001)to the control.It was similar to the CR rate by MTX and further ACTD in the control arm(89.1%vs.95.2%,P=0.135).Four patients experienced recurrence,with no death,during the 2-year follow-up.We demonstrated that chemotherapy initiation with single-course MTX may be an alternative regimen for patients with low-risk GTN. | Lili Chen Ling Xi Jie Jiang Rutie Yin Pengpeng Qu Xiuqin Li Xiaoyun Wan Yaxia Chen Dongxiao Hu Yuyan Mao Zimin Pan Xiaodong Cheng Xinyu Wang Qingli Li Danhui Weng Xi Zhang Hong Zhang Quanhong Ping Xiaomei Liu Xing Xie Beihua Kong Ding Ma Weiguo Lu | 2022 | Frontiers of Medicine2022，16，2： | 2 |
| 2 | 多西紫杉醇和卡铂联合治疗上皮性卵巢癌、原发性腹膜癌和输卵管癌的荟萃分析(英文)显示文摘Objective:The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian,primary peritoneal or fallopian tube cancers.Methods:Relevant articles were identified from MEDLINE(1993-2010),EMBASE(1980-2010),MEDION,the Cochrane library,Science Citation Index Expanded databases,hand searching of reference lists from primary articles and reviews,conference abstracts and contact with experts in the field.The review included 5 relevant primary studies(1430 women).Data was extracted for study characteristics and quality.Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests.A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.Results:The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxelcarboplatin group(OR = 1.33,95% CI = 1.13-1.56,P = 0.0005),whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin(OR = 1.0,95% CI = 0.87-1.16,P = 0.95).There were heterogeneity(χ2 = 79.36,P < 0.00001) and inconsistency(83.6%) in toxicity analysis among the trials,while neither heterogeneity(χ2 = 3.21,P = 0.99) nor inconsistency(I2 = 0%) in clinical responses among the trials.Conclusion:The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin.However,the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin. | Hongxiao Chen Yang Rao Pengpeng Qu | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，8： | 1 |
| 3 | Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria显示文摘 | Ting Hu Shuang Li Yile Chen Jian Shen Xiong Li Kecheng Huang Ru Yang Li Wu Zhilan Chen Yao Jia Shaoshuai Wang Xiaodong Cheng Xiaobing Han Zhongqiu Lin Hui Xing Pengpeng Qu Hongbing Cai Xiaojie Song Xiaoyu Tian Hongbing Xu Jun Xu Qinghua Zhang Ling Xi Dong | 2012 | European Journal of Cancer2012，，15： | 1 |
| 4 | 晚期卵巢癌化疗中CA125下降的临床意义(英文)显示文摘Objective:The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/epirubicin/ifosfamide (PAC) during early chemotherapy.The relationship between survival and CA125 regression during first line chemotherapy was evaluated.Methods:This retrospective investigation assessed 122 and 95 patients with stages IIc-IV ovarian carcinoma who underwent initial surgery followed by TP or PAC chemotherapy,respectively.Only epithelial ovarian cancers were included.CA125 half-life was calculated by mono-compartmental logarithmic regression.Every patient's nadir CA125 concentration was also studied.T-test was used in comparing CA125 half-life and nadir CA125 between two groups.Survival analyses for progression-free survival (PFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models for all of the patients.Results:There was not significant difference in CA125 half-life and nadir CA125 concentration between two groups (P > 0.05).CA125 half-life and nadir CA125 concentration had a univariate prognostic value for PFS and OS (P < 0.0001) in all of the patients.However pre-chemotherapy CA125 and different chemotherapy agents were not prognostic factors for PFS and for OS (P > 0.05,for each).In Cox models,CA125 half-life (P=0.0006),residual tumour (P < 0.0001),and nadir concentration (P=0.0032) were significant prognostic factors for disease free survival (DFS).For OS,CA125 half-life (P=0.0013),residual tumor (P < 0.0001),and nadir concentration (P=0.0118) were also the significant prognostic factors.Conclusion:There isn't significant difference in serum CA125 regression between patients who are treated with PAC or PT during early chemotherapy.CA125 half-life and nadir CA125 concentration are independent prognostic factor in advanced ovarian cancer. | Yuanjing Hu Pengpeng Qu | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员